A Narrative Review on Functionalized Nanoparticles for the Treatment and Early Detection of Hepatocellular Carcinoma
Source abstract
Abstract
(1) Background: Hepatocellular carcinoma (HCC) is a major global health issue, ranking among the most frequently diagnosed cancers and one of the leading causes of cancer-related mortality. (2) Methods: To identify studies that focus on nanotechnology-mediated treatment and early diagnosis in hepatocellular carcinoma, our group conducted a thorough literature search across major scientific databases. (3) Results: In this narrative review, we demonstrated that nanotechnology—particularly the use of nanoparticles—holds significant potential for both the treatment and early detection of hepatocellular carcinoma. Nanoparticles act as carriers for the targeted delivery of drugs to cancer cells, greatly enhancing treatment efficacy while minimizing adverse effects on healthy tissues. Due to their physicochemical properties, these nanoparticles can also carry contrast agents, enabling precise identification of tumor cells and contributing to the early diagnosis of hepatocellular carcinoma. (4) Conclusions: While significant progress has been made, challenges such as toxicity, cost, and regulatory hurdles remain.
Source: crossref · Quality: baseline
Research context
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Physiology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
Nanomedicine Department, Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania
3rd Surgery and Medical Clinic, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400162 Cluj-Napoca, Romania
Funding
“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
References (99)
Show source-provided references
1. The biology of Hepatocellular carcinoma: Implications for genomic and immune therapies10.1186/s12943-017-0712-x ↗
2. International Agency for Research on Cancer (2025, May 20). Global Cancer Observatory: Cancer Today. World Health Organization. Available online: https://gco.iarc.fr/today.
3. Bloom, M., Podder, S., Dang, H., and Lin, D. (2025). Advances in Immunotherapy in Hepatocellular Carcinoma. Int. J. Mol. Sci., 26.10.3390/ijms26051936 ↗
4. Hepatocellular Carcinoma and the Role of Liver Transplantation: An Update and Review
5. RNA nanotherapeutics for hepatocellular carcinoma treatment10.7150/thno.102964 ↗
6. Recent progress in treatment of hepatocellular carcinoma
7. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities10.2147/IJN.S236927 ↗
8. Nanoparticles as carriers for drug delivery in cancer10.1080/21691401.2018.1457039 ↗
9. Design of Nanoparticle-Based Carriers for Targeted Drug Delivery10.1155/2016/1087250 ↗
10. Nanoparticles: Emerging carriers for drug delivery10.1016/j.jsps.2011.04.001 ↗
11. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review10.1016/j.jare.2018.06.005 ↗
12. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma10.1016/j.biomaterials.2008.09.014 ↗
13. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice10.1016/j.ejpb.2015.03.003 ↗
14. Targeted treatment of hepatocellular carcinoma with aptamer-guided solid lipid nanoparticles loaded with norcantharidin10.1080/10717544.2025.2519470 ↗
15. Multifunctional Lactobionic Acid-Modified Dendrimers for Targeted Drug Delivery to Liver Cancer Cells: Investigating the Role Played by PEG Spacer10.1021/am504849x ↗
16. Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers10.1016/j.ijpharm.2017.06.049 ↗
17. Dendrimer based theranostic nanostructures for combined chemo- and photothermal therapy of liver cancer cells in vitro10.1016/j.colsurfb.2018.10.045 ↗
18. Effect of a controlled-release drug delivery system made of oleanolic acid formulated into multivesicular liposomes on hepatocellular carcinoma in vitro and in vivo10.2147/IJN.S108445 ↗
19. In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles10.1016/j.ejca.2006.08.029 ↗
20. Bonferoni, M.C., Gavini, E., Rassu, G., Maestri, M., and Giunchedi, P. (2020). Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting. Nanomaterials, 10.10.3390/nano10050870 ↗
21. Glycyrrhetinic acid-modified poly(ethylene glycol)–b-poly(γ-benzyl l-glutamate) micelles for liver targeting therapy10.1016/j.actbio.2010.04.021 ↗
22. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer10.1016/j.colsurfb.2018.11.082 ↗
23. Carbon Nanotubes: An Emerging Drug Carrier for Targeting Cancer Cells10.1155/2014/670815 ↗
24. Carbon nanotubes. A novel drug delivery system
25. Improved chemo-photothermal therapy of hepatocellular carcinoma using chitosan-coated gold nanoparticles10.1016/j.jphotobiol.2018.03.024 ↗
26. Siddique, S., and Chow, J.C.L. (2020). Gold Nanoparticles for Drug Delivery and Cancer Therapy. Appl. Sci., 10.10.3390/app10113824 ↗
27. Construction and application of a liver cancer-targeting drug delivery system based on core–shell gold nanocages10.2147/IJN.S151043 ↗
28. Grześkowiak, B.F., Maziukiewicz, D., Kozłowska, A., Kertmen, A., Coy, E., and Mrówczyński, R. (2021). Polyamidoamine Dendrimers Decorated Multifunctional Polydopamine Nanoparticles for Targeted Chemo- and Photothermal Therapy of Liver Cancer Model. Int. J. Mol. Sci., 22.10.3390/ijms22020738 ↗
29. A self-assembly nanodrug delivery system based on amphiphilic low generations of PAMAM dendrimers-ursolic acid conjugate modified by lactobionic acid for HCC targeting therapy10.1016/j.nano.2017.10.007 ↗
30. Xu, Y., Guo, X., Tu, L., Zou, Q., Li, Q., Tang, C., Chen, B., Wu, C., and Wei, M. (2015). Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Int. J. Nanomed., 5123.10.2147/IJN.S87011 ↗
31. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma10.1016/j.ijpharm.2018.05.007 ↗
32. Dual-Ligand Functionalized Core-Shell Chitosan-Based Nanocarrier for Hepatocellular Carcinoma-Targeted Drug Delivery10.2147/IJN.S240359 ↗
33. Folate chitosan conjugated doxorubicin and pyropheophorbide acid nanoparticles (FCDP–NPs) for enhance photodynamic therapy10.1039/C7RA08757H ↗
34. Regulated pH-Responsive Polymeric Micelles for Doxorubicin Delivery to the Nucleus of Liver Cancer Cells10.1166/jbn.2016.2247 ↗
35. Hyper-branched multifunctional carbon nanotubes carrier for targeted liver cancer therapy10.1016/j.arabjc.2021.103649 ↗
36. Single walled carbon nanotubes as drug delivery vehicles: Targeting doxorubicin to tumors10.1016/j.biomaterials.2011.11.004 ↗
37. Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells
38. Combined chemo/photothermal therapy based on mesoporous silica-Au core-shell nanoparticles for hepatocellular carcinoma treatment10.1080/03639045.2019.1629688 ↗
39. Farinha, P., Coelho, J.M.P., Reis, C.P., and Gaspar, M.M. (2021). A Comprehensive Updated Review on Magnetic Nanoparticles in Diagnostics. Nanomaterials, 11.10.3390/nano11123432 ↗
40. Magnetic Nanoparticles for Hepatocellular Carcinoma Diagnosis and Therapy10.15403/jgld.2014.1121.253.nan ↗
41. Guo, W., Song, X., Liu, J., Liu, W., Chu, X., and Lei, Z. (2024). Quantum Dots as a Potential Multifunctional Material for the Enhancement of Clinical Diagnosis Strategies and Cancer Treatments. Nanomaterials, 14.10.3390/nano14131088 ↗
42. Yu, X., Chen, L., Li, K., Li, Y., Xiao, S., Luo, X., Liu, J., Zhou, L., Deng, Y., and Pang, D. (2007). Immunofluorescence detection with quantum dot bioconjugates for hepatoma in vivo. J. Biomed. Opt., 12.10.1117/1.2437744 ↗
43. Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer-conjugated quantum dots and magnetic particles10.1016/j.biomaterials.2013.02.018 ↗
44. Nano-enabled theranostics for cancer10.1039/D1MA00069A ↗
45. Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma10.2147/IJN.S128525 ↗
46. Synthesis and application of strawberry-like Fe3O4-Au nanoparticles as CT-MR dual-modality contrast agents in accurate detection of the progressive liver disease10.1016/j.biomaterials.2015.02.019 ↗
47. PLinaS-g-PEG coated magnetic nanoparticles as a contrast agent for hepatocellular carcinoma diagnosis10.1080/09205063.2020.1764183 ↗
48. Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma10.1126/sciadv.abo6406 ↗
49. Kozenkova, E., Levada, K., Efremova, M.V., Omelyanchik, A., Nalench, Y.A., Garanina, A.S., Pshenichnikov, S., Zhukov, D.G., Lunov, O., and Lunova, M. (2020). Multifunctional Fe3O4-Au Nanoparticles for the MRI Diagnosis and Potential Treatment of Liver Cancer. Nanomaterials, 10.10.3390/nano10091646 ↗
50. Co-delivery of hydrophilic/hydrophobic drugs by multifunctional yolk-shell nanoparticles for hepatocellular carcinoma theranostics10.1016/j.cej.2020.124416 ↗
51. Yoo, J., Park, C., Yi, G., Lee, D., and Koo, H. (2019). Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems. Cancers, 11.10.3390/cancers11050640 ↗
52. Cannito, S., Bincoletto, V., Turato, C., Pontisso, P., Scupoli, M.T., Ailuno, G., Andreana, I., Stella, B., Arpicco, S., and Bocca, C. (2022). Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells. Molecules, 27.10.3390/molecules27031062 ↗
53. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration10.2147/IJN.S184379 ↗
54. In vitro and in vivo evaluation of self-assembled chitosan nanoparticles selectively overcoming hepatocellular carcinoma via asialoglycoprotein receptor10.1080/10717544.2021.1983077 ↗
55. Takke, A., and Shende, P. (2019). Nanotherapeutic silibinin: An insight of phytomedicine in healthcare reformation. Nanomed. Nanotechnol. Biol. Med., 21.10.1016/j.nano.2019.102057 ↗
56. Folate-targeted nanomicelles containing silibinin as an active drug delivery system for liver cancer therapy10.1016/j.jddst.2020.102157 ↗
57. Wu, J. (2021). The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. J. Pers. Med., 11.10.3390/jpm11080771 ↗
58. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles10.1016/j.biomaterials.2011.01.021 ↗
59. Onzi, G., Guterres, S.S., Pohlmann, A.R., and Frank, L.A. (2021). Passive Targeting and the Enhanced Permeability and Retention (EPR) Effect. The ADME Encyclopedia, Springer International Publishing.10.1007/978-3-030-51519-5_108-1 ↗
60. pH-sensitive Liposomes for Drug Delivery in Cancer Treatment10.4155/tde.13.80 ↗
61. Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles10.1016/j.ejpb.2019.05.006 ↗
62. Transport of molecules in the tumor interstitium: A review
63. Subhan, M.A., Parveen, F., Filipczak, N., Yalamarty, S.S.K., and Torchilin, V.P. (2023). Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis. J. Pers. Med., 13.10.3390/jpm13030389 ↗
64. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma10.7150/thno.54822 ↗
65. Stepwise targeting and responsive lipid-coated nanoparticles for enhanced tumor cell sensitivity and hepatocellular carcinoma therapy10.7150/thno.42008 ↗
66. Therapeutic siRNA: Principles, challenges, and strategies
67. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis10.1016/S0092-8674(00)80108-7 ↗
68. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma10.1021/acs.biomac.8b00358 ↗
69. Rodponthukwaji, K., Pingrajai, P., Jantana, S., Taya, S., Duangchan, K., Nguyen, K.T., Srisawat, C., and Punnakitikashem, P. (2023). Epigallocatechin Gallate Potentiates the Anticancer Effect of AFP-siRNA-Loaded Polymeric Nanoparticles on Hepatocellular Carcinoma Cells. Nanomaterials, 14.10.3390/nano14010047 ↗
70. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy10.2147/IJN.S157519 ↗
71. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity10.1126/science.1225829 ↗
72. Targeting Hepatitis B Virus With CRISPR/Cas910.1038/mtna.2014.68 ↗
73. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells10.1002/jcb.27050 ↗
74. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway10.1186/s13046-019-1462-y ↗
75. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B10.3748/wjg.v27.i14.1369 ↗
76. Fan, Z., Zhuang, C., Wang, S., and Zhang, Y. (2021). Photodynamic and Photothermal Therapy of Hepatocellular Carcinoma. Front. Oncol., 11.10.3389/fonc.2021.787780 ↗
77. Tumor-Targeting Multifunctional Nanoprobe for Enhanced Photothermal/Photodynamic Therapy of Liver Cancer10.1021/acs.langmuir.0c03578 ↗
78. Ailioaie, L.M., Ailioaie, C., and Litscher, G. (2023). Synergistic Nanomedicine: Photodynamic, Photothermal and Photoimmune Therapy in Hepatocellular Carcinoma: Fulfilling the Myth of Prometheus?. Int. J. Mol. Sci., 24.10.3390/ijms24098308 ↗
79. Photothermal treatment of liver cancer with albumin-conjugated gold nanoparticles initiates Golgi Apparatus–ER dysfunction and caspase-3 apoptotic pathway activation by selective targeting of Gp60 receptor10.2147/IJN.S86495 ↗
80. Huang, A.-T., Du, J., Liu, Z.-Y., Zhang, G.-C., Abuduwaili, W., Yan, J.-Y., Sun, J.-L., Xu, R.-C., Liu, T.-T., and Shen, X.-Z. (2022). Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma. Nanomaterials, 12.10.3390/nano12183191 ↗
81. Kumar, A., Moralès, O., Mordon, S., Delhem, N., and Boleslawski, E. (2021). Could Photodynamic Therapy Be a Promising Therapeutic Modality in Hepatocellular Carcinoma Patients? A Critical Review of Experimental and Clinical Studies. Cancers, 13.10.3390/cancers13205176 ↗
82. Ogbodu, R.O., Nitzsche, B., Ma, A., Atilla, D., Gürek, A.G., and Höpfner, M. (2020). Photodynamic therapy of hepatocellular carcinoma using tetra-triethyleneoxysulfonyl zinc phthalocyanine as photosensitizer. J. Photochem. Photobiol. B Biol., 208.10.1016/j.jphotobiol.2020.111915 ↗
83. Immunotherapy in hepatocellular carcinoma10.1016/j.aohep.2019.04.003 ↗
84. Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases10.1039/D2NH00289B ↗
85. Immunotherapy of Tumor RNA-Loaded Lipid Nanoparticles Against Hepatocellular Carcinoma10.2147/IJN.S291421 ↗
86. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma10.7150/thno.85843 ↗
87. Da, X., Cao, B., Mo, J., Xiang, Y., Hu, H., Qiu, C., Zhang, C., Lv, B., Zhang, H., and He, C. (2024). Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets. BMC Cancer, 24.10.1186/s12885-024-12006-1 ↗
88. Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy10.1039/D2NA00322H ↗
89. Toxicity and Biocompatibility of Carbon Nanoparticles10.1166/jnn.2006.125 ↗
90. Biocompatibility and Toxicity of Nanoparticles and Nanotubes10.1155/2012/548389 ↗
91. Liu, X., Bai, Y., Zhou, B., Yao, W., Song, S., Liu, J., and Zheng, C. (2024). Recent advances in hepatocellular carcinoma-targeted nanoparticles. Biomed. Mater., 19.10.1088/1748-605X/ad46d3 ↗
92. Baig, B., Halim, S.A., Farrukh, A., Greish, Y., and Amin, A. (2019). Current status of nanomaterial-based treatment for hepatocellular carcinoma. Biomed. Pharmacother., 116.10.1016/j.biopha.2019.108852 ↗
93. Understanding Nanomaterial–Liver Interactions to Facilitate the Development of Safer Nanoapplications10.1002/adma.202106456 ↗
94. Mechanism of hard-nanomaterial clearance by the liver10.1038/nmat4718 ↗
95. Nanomedicine Scale-up Technologies: Feasibilities and Challenges10.1208/s12249-014-0177-9 ↗
96. Mülhopt, S., Diabaté, S., Dilger, M., Adelhelm, C., Anderlohr, C., Bergfeldt, T., Gómez De La Torre, J., Jiang, Y., Valsami-Jones, E., and Langevin, D. (2018). Characterization of Nanoparticle Batch-To-Batch Variability. Nanomaterials, 8.10.3390/nano8050311 ↗
97. At the Crossroads of Nanotoxicology in vitro: Past Achievements and Current Challenges10.1093/toxsci/kfv106 ↗
98. Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma10.1186/s40164-025-00658-z ↗
99. Nanotechnology: Regulatory Outlook on Nanomaterials and Nanomedicines in United States, Europe and India